Navigation Links
Wyeth Announces Election of Bernard Poussot as CEO of Company Effective January 1, 2008
Date:9/27/2007

MADISON, N.J., Sept. 27 /PRNewswire-FirstCall/ -- Wyeth (NYSE: WYE) today announced the election of Bernard Poussot to the position of President and Chief Executive Officer, Wyeth, effective January 1, 2008. Mr. Poussot began his career at Wyeth in 1986. In 1996, he was appointed President of Wyeth- Ayerst International, and he was promoted to President of the worldwide pharmaceutical business in 1997. In 2002, he was promoted to Executive Vice President, Wyeth, assuming responsibility for Wyeth R&D. In April 2006, Mr. Poussot was promoted to President and Vice Chairman, Wyeth, and in January 2007 to the position of President, Chief Operating Officer and Vice Chairman, Wyeth.

The Company announced that Robert Essner, Chairman and Chief Executive Officer, intends to remain in his current positions through the end of 2007 and then will continue as Chairman of the Board of Directors for a period of transition. Mr. Essner joined Wyeth in 1989. In 1997, he was elected to the position of Executive Vice President and member of the Board of Directors. In 2000, he was elected President and Chief Operating Officer. Mr. Essner was elected Chief Executive Officer in May 2001 and Chairman in January 2003. "The election of Mr. Poussot is a result of the Company's ongoing succession management process that has been an important focus of the Wyeth Board of Directors and management. Bernard is exceptionally well-qualified for this role, and we have built a world-class management team to support him and the Company," says Robert Essner.

Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products and non-prescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.


'/>"/>
SOURCE Wyeth
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Wyeth Launches Vaccine for Pneumococcal Disease in India
2. Wyeth Embroiled in a Lawsuit over its Hormone Replacement Therapy
3. Wyeth Pharma Wins Law Suit
4. Verdict Against Wyeth Pharma in Prempro Case
5. FDA Approves Wyeths Oral Contraceptive Lybrel
6. PM announces a new health care order for India
7. Ramdoss Announces Introduction of RCH-II
8. Britain Announces Third Transfusion Related Mad Cow Case
9. Gates Foundation Announces $287 Million In Grants Towards AIDS Vaccine
10. Tibet Announces the Dalai Lama’s Tour of South Americ
11. NHS announces further Cost cutting Measures
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... ... April 21, 2017 , ... Brady (NYSE:BRC), a ... B-595 and B-7569 vinyl label materials received certification for the ... are tested to remain intact and legible, for use on chemical drums shipped by ...
(Date:4/21/2017)... , ... April 21, 2017 , ... The adage “Show, ... House, the next project in the company’s esteemed VISION House demonstration project series. Manifesting ... exactly the amount of resources they need to live affordably and abundantly without unduly ...
(Date:4/21/2017)... (PRWEB) , ... April 21, 2017 , ... The Hong ... the first 3D printing facility among higher education institutions in Hong Kong to support ... in terms of the range and quantity of facilities in Hong Kong. , ...
(Date:4/21/2017)... ... 2017 , ... Alive for Wellness is a group of clinical ... struggles. The Alive team uses advanced behavioral sciences treatment modalities to accomplish their ... mental health struggle is based on 10 modalities of treatment that include: ...
(Date:4/21/2017)... ... April 21, 2017 , ... Metrasens is honoured to ... the UK’s most prestigious award for business success. The company has been ... and has grown by a total of 400% over the last six years. ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... April 19, 2017  Novartis today announced the ... Heart, Lung, and Blood Institute (NHLBI) of the ... of patients with treatment-naïve severe aplastic anemia (SAA) ... with eltrombopag at the initiation of and concurrently ... evaluated three sequential treatment groups, or cohorts. Cohort ...
(Date:4/18/2017)... -- Research and Markets has announced the addition of ... offering. ... market to grow at a CAGR of 6.35% during the period ... has been prepared based on an in-depth market analysis with inputs ... growth prospects over the coming years. The report also includes a ...
(Date:4/18/2017)... 2017  Spero Therapeutics, LLC, a biopharmaceutical company founded ... infections, will present preclinical data supporting the use of ... (MDR) Gram-negative infections at the 27th European Congress of ... in Vienna, Austria . ... "Our ongoing preclinical ...
Breaking Medicine Technology: